Cite
MO10-2 Association of pre-existing interstitial lung abnormalities with immune checkpoint inhibitor-induced interstitial lung disease among patients with non-lung cancers.
MLA
Shimoji, Kiyofumi, et al. “MO10-2 Association of Pre-Existing Interstitial Lung Abnormalities with Immune Checkpoint Inhibitor-Induced Interstitial Lung Disease among Patients with Non-Lung Cancers.” Annals of Oncology, vol. 32, July 2021, p. S302. EBSCOhost, https://doi.org/10.1016/j.annonc.2021.05.585.
APA
Shimoji, K., Masuda, T., Yamaguchi, K., Sakamoto, S., Horimasu, Y., Nakashima, T., Miyamoto, S., Iwamoto, H., Fujitaka, K., Hamada, H., Takeno, S., Hide, M., Teishima, J., Ohdan, H., & Hattori, N. (2021). MO10-2 Association of pre-existing interstitial lung abnormalities with immune checkpoint inhibitor-induced interstitial lung disease among patients with non-lung cancers. Annals of Oncology, 32, S302. https://doi.org/10.1016/j.annonc.2021.05.585
Chicago
Shimoji, Kiyofumi, Takeshi Masuda, Kakuhiro Yamaguchi, Shinjiro Sakamoto, Yasushi Horimasu, Taku Nakashima, Shintaro Miyamoto, et al. 2021. “MO10-2 Association of Pre-Existing Interstitial Lung Abnormalities with Immune Checkpoint Inhibitor-Induced Interstitial Lung Disease among Patients with Non-Lung Cancers.” Annals of Oncology 32 (July): S302. doi:10.1016/j.annonc.2021.05.585.